> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Orphan Status for Epygenix Epilepsy Drug
- URL: https://www.fdaweb.com/orphan-status-for-epygenix-epilepsy-drug/
- Published: 2017-08-24T12:00:00.000Z
- Updated: 2026-09-14T22:43:12.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139470

FDA has granted Epygenix Therapeutics an Orphan Drug Designation for EPX-300 for treating patients with Dravet Syndrome, a lifelong form of epilepsy that begins in the first year of life with frequent or prolonged seizures. “The effectiveness of EPX-300 was discovered using a proprietary phenotype-based zebrafish drug screening platform,” the company says. “The zebrafish harbors 82% of human disease-associated genes, and shares many physiological and metabolic pathways with humans. Using the zebrafish model for Dravet Syndrome, drug candidates were identified from a screen of more than 3,000 drugs that suppress seizures and symptoms associated with neurological diseases.”